Balance Sheet Position - Standalone (as of September 30, 2026)
Total assets: ₹216,195.60 lakh (compared to ₹193,545.42 lakh as of March 31, 2026)
Property, plant and equipment: ₹77,248.51 lakh
Capital work-in-progress: ₹6,649.63 lakh
Inventories: ₹27,386.43 lakh
Trade receivables: ₹35,247.20 lakh
Cash and cash equivalents: ₹26,337.16 lakh
Total equity: ₹186,481.96 lakh
Equity share capital: ₹4,093.56 lakh (face value ₹5 each)
Other equity: ₹182,388.40 lakh
Balance Sheet Position - Consolidated (as of September 30, 2026)
Total assets: ₹222,088.30 lakh (compared to ₹198,396.43 lakh as of March 31, 2026)
Property, plant and equipment: ₹95,450.06 lakh
Capital work-in-progress: ₹6,694.57 lakh
Goodwill: ₹10,434.10 lakh
Inventories: ₹28,028.11 lakh
Trade receivables: ₹35,831.14 lakh
Cash and cash equivalents: ₹28,876.74 lakh
Total equity: ₹192,036.49 lakh
Equity share capital: ₹4,093.56 lakh
Other equity: ₹181,651.18 lakh
Cash Flow Statement - Standalone (H1 FY2026)
Cash from operating activities: ₹21,613.41 lakh
Cash used in investing activities: ₹(7,353.09) lakh
Cash used in financing activities: ₹(13,966.42) lakh
Net increase in cash: ₹10,293.90 lakh
Cash Flow Statement - Consolidated (H1 FY2026)
Cash from operating activities: ₹21,591.90 lakh
Cash used in investing activities: ₹(12,775.15) lakh
Cash used in financing activities: ₹(14,055.70) lakh
Net increase in cash: ₹4,761.05 lakh
Subsidiary and Joint Venture Updates
The consolidated results include: Acutaas Chemicals Electrolytes Private Limited, Acutaas Advance Material Limited, Baba Fine Chemicals (Partnership Firm), Ami Onco-Theronostics, LLC (Joint Venture), Enchem Ami Organics Private Limited (Step-down subsidiary), and Indichem Inc. (Step-down subsidiary)
Indichem Inc., a step-down subsidiary incorporated in South Korea, inaugurated its semiconductor materials manufacturing plant at Gongju, Chungcheongnam-do, South Korea on August 28, 2026
Acutaas Advance Material Limited holds 75% share capital of Indichem Inc. with investment of KRW 30 billion (approximately ₹200 crore)
The facility was under trial runs as of September 30, 2026
On October 17, 2026 (subsequent to quarter end), the Company completed acquisition of 100% equity share capital of Enchem Ami Organics Private Limited from Acutaas Chemicals Electrolytes Private Limited, making it a direct wholly owned subsidiary
Segment Information
The Company operates in a single segment: Custom synthesis and manufacturing of Speciality Chemicals having application in Pharmaceuticals API and others
Dates and Meetings
Board meeting held on October 27, 2026 (commenced at 11:30 AM, concluded at 2:35 PM)
